Samples were collected at admission, and days 3, 7, and 14 for patients staying as long as 14 days. All patients had 10 cc of EDTA-treated blood, 10 cc of citrate-treated blood (at 3.2%), and 5 cc of sodium heparin-treated blood collected. CBC was tested on the EDTA samples with an automated SYSMEX XN-10 instrument (Sysmex Corporation, Kobe, Japan). Serum creatinine and C reactive protein were measured with a COBAS 601 automated chemistry analyzer (Roche Diagnostics, Basel, Switzerland).
The samples for coagulation tests were centrifuged within 2 h after collection and divided into aliquots for testing of coagulation markers including PT/INR, aPTT, D-dimer level, and fibrinogen (FIB) at all four time points. Antithrombin III (AT), protein C (PC), protein S (PS), von Willebrand factor antigen (vWFAg), and factor VIII (FVIII) activity testing was performed with a STAR Max® instrument (Diagnostica Stago, Marseille, France) after patient admission to the hospital.
The VTE and DIC scores were calculated for all admitted patients at admission, and days 3, 7, and 14. Mortality was defined as the number of deaths among all participants and is reported as a percentage.
The samples for coagulation tests were centrifuged within 2 h after collection and divided into aliquots for testing of coagulation markers including PT/INR, aPTT, D-dimer level, and fibrinogen (FIB) at all four time points. Antithrombin III (AT), protein C (PC), protein S (PS), von Willebrand factor antigen (vWFAg), and factor VIII (FVIII) activity testing was performed with a STAR Max® instrument (Diagnostica Stago, Marseille, France) after patient admission to the hospital.
The VTE and DIC scores were calculated for all admitted patients at admission, and days 3, 7, and 14. Mortality was defined as the number of deaths among all participants and is reported as a percentage.